Mazonakis Emmanouil, Stirling Catherine, Booth Karen L, McClenahan Jenny, Heron Neil, Geddes Colin C
Western Infirmary of Glasgow, UK.
Hemodial Int. 2009 Jan;13(1):6-10. doi: 10.1111/j.1542-4758.2009.00327.x.
Access-related bacteremia is an important cause of morbidity in chronic hemodialysis patients. The incidence of bacteremia is higher in patients dialyzing through a tunneled central venous catheter (TCVC) compared with an arteriovenous fistula (AVF). Our aim was to explore if this is explained by patient comorbidity. Two groups of chronic hemodialysis outpatients were compared: all patients who dialyzed through a TCVC at any time during 2003 and were fit enough to subsequently have a functioning AVF or renal transplant even if it was after 2003 (Group 1; n=93); and all patients who dialyzed through a TCVC in 2003 and were not fit enough to have a functioning AVF or renal transplant (Group 2; n=119). Episodes of bacteremia (n=71) were identified and those not related to access were excluded. Patients in Group 1 were younger than Group 2 (57.5 years vs. 64.8 years; P=0.001). The incidences of bacteremia in Groups 1 and 2 were, respectively, 0.31 and 0.44 episodes per 1000 patient days while dialyzing through an AVF (P=0.77), and 2.21 and 2.27 per 1000 days while dialyzing through a TCVC (P=0.91). The 3-year actual survival from January 1, 2003 to January 1, 2006 was significantly higher in Group 1 than in Group 2 (80.6% vs. 26.1%; P<0.0001) confirming the higher comorbidity of the patients in Group 2. Patients dialyzing through a TCVC (compared with an AVF) have a significantly higher risk of access-related bacteremia, irrespective of comorbidity.
与血管通路相关的菌血症是慢性血液透析患者发病的重要原因。与动静脉内瘘(AVF)相比,通过隧道式中心静脉导管(TCVC)进行透析的患者菌血症发生率更高。我们的目的是探讨这是否可以用患者的合并症来解释。比较了两组慢性血液透析门诊患者:2003年期间任何时候通过TCVC进行透析且身体状况足以随后拥有功能正常的AVF或肾移植的所有患者,即使是在2003年之后(第1组;n = 93);以及2003年通过TCVC进行透析且身体状况不足以拥有功能正常的AVF或肾移植的所有患者(第2组;n = 119)。确定了菌血症发作(n = 71)并排除了与血管通路无关的发作。第1组患者比第2组患者年轻(57.5岁对64.8岁;P = 0.001)。第1组和第2组在通过AVF透析时菌血症的发生率分别为每1000患者日0.31次和0.44次发作(P = 0.77),在通过TCVC透析时分别为每1000日2.21次和2.27次发作(P = 0.91)。从2003年1月1日至2006年1月1日的3年实际生存率第1组显著高于第2组(80.6%对26.1%;P<0.0001),证实了第2组患者合并症更高。与AVF相比,通过TCVC进行透析的患者发生与血管通路相关菌血症的风险显著更高,与合并症无关。